Bial - Portela C S.A.
bial.comTotal trials
136
Active
2
Phase 3
13
Total enrollment
12,897
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Opicapone 50 mg | — | — | — | 3 | |||
| SL-APO | — | — | — | — | — | 1 |
Next readouts
- 2028-02
- 2028-10-31
Top conditions
- Epilepsy36
- Parkinson Disease31
- Parkinson's Disease14
- Pulmonary Arterial Hypertension12
- Parkinson's Disease (PD)11
- Hypertension6
- Partial Epilepsy6
- Chronic Heart Failure3
Frequently asked questions about Bial - Portela C S.A.
- How many clinical trials does Bial - Portela C S.A. have on ClinicalTrials.gov?
- Bial - Portela C S.A. is listed as the lead sponsor on 136 clinical trials in ClinicalTrials.gov, 2 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Bial - Portela C S.A.'s trials are in Phase 3?
- 13 of Bial - Portela C S.A.'s trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Bial - Portela C S.A. focus on?
- Bial - Portela C S.A.'s most-studied conditions on ClinicalTrials.gov are Epilepsy, Parkinson Disease, Parkinson's Disease, Pulmonary Arterial Hypertension, Parkinson's Disease (PD).
- When are Bial - Portela C S.A.'s next clinical trial readouts?
- Bial - Portela C S.A. has 2 upcoming primary-completion readouts tracked here; the soonest is “SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment”, expected around 2028-02.